Evolution of Cellular and Humoral Immunity During and After a Three Doses-Course of mRNA-1273 COVID-19 Vaccine in Kidney Transplant Recipients
1Hospital Clínic de Barcelona, Barcelona, Spain, 2Hospital Clinic de Barcelona, Barcelona, Spain, 3Nephrology and Renal Transplantation, Hospital Clinic of Barcelona, Barcelona, Spain, 4Laboratori Experimental de Nefrologia i Trasplantament (LENIT), IDIBAPS, Barcelona, Spain, 5IDIBAPS, Barcelona, Spain, 6Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain
Meeting: 2022 American Transplant Congress
Abstract number: 546
Keywords: Antibodies, COVID-19, T cells, Vaccination
Topic: Clinical Science » Infection Disease » 25 - Kidney Infectious Non-Polyoma & Non-Viral Hepatitis
Session Information
Session Name: Kidney Transplant Infections
Session Type: Rapid Fire Oral Abstract
Date: Tuesday, June 7, 2022
Session Time: 5:30pm-7:00pm
Presentation Time: 5:50pm-6:00pm
Location: Hynes Ballroom B
*Purpose: Seroconversion after a 2 doses of mRNA COVID-19 vaccine in kidney transplant recipients (KTR) ranges between 30 and 50% in different series. We previously demonstrated that a substantial proportion of KTRs (35%) without a humoral response, develops a cellular response after the second dose assessed by the ELISpot technique. We aim to study the evolution of both humoral and cellular response in the same cohort before and 1 month after the administration of the third dose of mRNA-1273 COVID-19 vaccine.
*Methods: We included in the final analysis KTRs without evidence of previous exposure to COVID-19 and who were not infected during the course of the study and with complete data in all the time-points (n=105). The four time-points studied were at baseline before the first dose (T1), after the second dose (T2, 2 months) and before (T3, 6 months) and after (T4, 7 months) the administration of the third dose of 100mcg mRNA-1273 COVID-19 vaccine. In all the time points, IgG and IgM titre against protein S assessed by Luminex technique and cellular immunity assessed by N- and S-protein specific ELISpot were studied.
*Results: The percentage of patients with a positive humoral or cellular immunity against the S-protein were 24.8% and 51.4% after the second dose (T2). This percentages changed to 54.3% and 48.6% at 6 months (T3), respectively for IgG and S-ELISpot, in the absence of proven COVID-19. After the administration of the 3rd dose (T4) these percentages increased to 75.2% for IgG and 61.0% of S-ELISpot respectively. At multivariate analysis, the only factor that was positively associated with IgG development at T4 was S-ELIspot positivity after the 2nd dose (T2) [OR(CI) 3.14[1.10-8.96], p=0.032). Factors negatively associated with seroconversion were being transplanted during the last year [OR(CI) 0.23[0.07-0.80], P=0.021] and previous transplantation [OR(CI) 0.22[0.06-0.78], P=0.020).
*Conclusions: After a 3 doses-course of mRNA-1273 COVID-19 vaccine, three quarters of kidney transplant recipients developed finally IgG against protein S. Developing a cellular response after the second dose was positively associated with the final seroconversion, while being transplanted previously or being vaccinated during the first year after KT impacted negatively on the vaccine outcome.
To cite this abstract in AMA style:
Cucchiari D, Egri N, Casals-Urquiza J, Risco-Zevallos JDel, Rodríguez-Espinosa D, Montagud-Marrahi E, Rovira J, Ramirez-Bajo M, Banón-Maneus E, Ventura-Aguiar P, Pascal M, Revuelta I, Bayès B, Diekmann F. Evolution of Cellular and Humoral Immunity During and After a Three Doses-Course of mRNA-1273 COVID-19 Vaccine in Kidney Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/evolution-of-cellular-and-humoral-immunity-during-and-after-a-three-doses-course-of-mrna-1273-covid-19-vaccine-in-kidney-transplant-recipients/. Accessed May 18, 2025.« Back to 2022 American Transplant Congress